STOCK TITAN

Lantern Pharma Inc - LTRN STOCK NEWS

Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.

Lantern Pharma Inc. (LTRN) leverages artificial intelligence and precision medicine to revolutionize oncology drug development. This news hub provides investors and researchers with timely updates on the company's progress in transforming cancer treatment through biomarker-driven approaches.

Access centralized, reliable information on clinical trial milestones, strategic collaborations, and regulatory developments. Our curated news collection simplifies tracking of AI-powered drug discovery advancements and therapeutic pipeline updates specific to Lantern Pharma's innovative platform.

Discover how machine learning accelerates oncology research while maintaining focus on genetic screening precision. The page serves as an essential resource for understanding the company initiatives shaping personalized cancer therapies.

Bookmark this page for streamlined access to verified announcements and analysis-free updates directly impacting Lantern Pharma's position in biotechnology innovation.

Rhea-AI Summary
Lantern Pharma to present positive data on its drug candidate LP-284 for non-Hodgkin’s lymphoma at SOHO Annual Meeting. Phase 1 clinical trials expected to start in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.64%
Tags
conferences
-
Rhea-AI Summary
Lantern Pharma expands RADR® platform for improved immune checkpoint inhibitor (ICI) drug development
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.72%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
none
Rhea-AI Summary
Lantern Pharma announces operational highlights and financial results for Q2 2023, including FDA clearance for LP-184 and completion of IND-enabling studies for LP-284. Cash runway until 2025 with $48.0 million in cash, cash equivalents, and marketable securities. Collaboration with Bielefeld University for ADC development. LP-184 Phase 1 trial targeting relapsed/refractory advanced solid tumors and brain cancers. LP-284 Phase 1 trial targeted for Q4 in advanced non-Hodgkin’s lymphomas. Phase 2 trial for LP-300 in never smokers with NSCLC. Patent allowance for LP-284 extending commercial protection until early 2039.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.07%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.29%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.94%
Tags
AI
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.16%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
Lantern Pharma Inc

Nasdaq:LTRN

LTRN Rankings

LTRN Stock Data

33.54M
9.20M
14.72%
23.34%
2.15%
Biotechnology
Pharmaceutical Preparations
Link
United States
DALLAS